Effect of Intraoperative Epidural Block and Sufentanil TCI on Stress Response, Immune Function and Prognosis in Patients Undergoing Open Hepatic Lobectomy

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035299

Enrollment

Unknown

Registered

2020-08-07

Start date

2020-08-09

Completion date

Unknown

Last updated

2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hepatic carcinoma

Interventions

Epidural Block:Epidural Block

Sufentanil TCI:Sufentanil TCI

Eligibility

Sex/Gender

All

Age

18 Years to 68 Years

Inclusion criteria

Inclusion criteria: 1. Undergoing open hepatic lobectomy for primary HCC; 2. ASA I-II; 3. Be willing to take part in the project and sign the ICF.

Exclusion criteria

Exclusion criteria: 1. Aged over 68 or under 18 years; 2. HCC recurrence; 3. With severe systematic illness; 4. With severe endocrine disease, immune disease or under immunosuppressive treatments and hormonal therapy; 5. Contradictions for epidural block; 6. Be allergic to medicine used in the project; 7. Combined surgery/ emergency surgery; 8. Pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
IL-4;IFN-?;TGF-ß;CD3+Tcell;CD4+Tcell;CD8+Tcell;NK cell;fingertip blood glucose;cortisol;TNF-a;IL-6;	—

Secondary

Measure	Time frame
blood pressure;VAS score;Total usage of Sufentanil;Duration of surgery;Adverse events;	—

Countries

China

Contacts

Public ContactFang Fang

Fang.fang@zs-hospital.sh.cn+86 13681972715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026